The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...

Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in ...

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

Intensifying competition, pricing pressure and copycat versions of its weight-loss drugs are holding back sales at the pharma ...

The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through ...

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

A Novo Nordisk executive collapsed during President Trump’s announcement about lowering the cost of weight loss drugs like ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

Eli Lilly and Novo Nordisk are cutting prices for popular weight-loss drugs in deals struck with the Trump administration, ...

Novo Nordisk’s weaker results indicate mounting pressure in the weight-loss drug market that it once dominated. The maker of Ozempic and Wegovy is facing tougher competition, slower demand, and ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...